Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)

US11311527B2 · kind B2 · utility

Assignee

• FORMA Therapeutics, Inc. · US

Inventors

• Patrick F. Kelly · Concord, US
• Susan Ashwell · Plainsboro, US
• Blythe Thomson · Cincinnati, US
• Alan Collis · Lexington, US
• Jeff Davis · Hingham, US
• Duncan Walker · Boulder, US
• Wei Lu · Newton, US

Key dates

• Filing date: Jun 4, 2020
• Grant date: Apr 26, 2022
• Expiry date: Jun 4, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.